Endometrial Cancer Trial, Recruiting NCT05401175 Sponsor: Chongqing University Cancer Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05401175
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 60 years old.
  • People with cervical cancer where both radiation therapy and chemotherapy are considered appropriate treatments.
  • People whose cervical cancer has been confirmed by pathology to be squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
  • People with a performance status score of 1 or lower on the ECOG scale, meaning they are generally able to carry out daily activities with little or no restriction (confirm with trial site).
  • People with an expected survival of more than 3 months.
  • Women who are pre-menopausal, or women who have been post-menopausal for at least 12 months, and who have a negative pregnancy test result.
  • People who agree to use effective contraception throughout the study and for 6 months after treatment ends.
  • People who are willing to participate voluntarily, sign a consent form, and are able to attend all study visits and follow-up appointments.

Who may not be able to join:

  • People who have been clinically diagnosed with a bone marrow disease.
  • People where imaging or pathology has identified cancer that has spread to the central nervous system, the lining of the brain, bones, or bone marrow.
  • People with severe heart failure.
  • People who have previously had an allogeneic stem cell transplant or an organ transplant.
  • People with active bleeding or a condition called autoimmune thrombocytopenic purpura (a disorder affecting blood platelets).
  • People for whom radiation therapy or chemotherapy is medically unsuitable or contraindicated.
  • People who test positive for HIV.
  • People with an active hepatitis B or hepatitis C infection (either acute or chronic).
  • People with a history of certain serious digestive system conditions within the past 6 months, including bowel perforation or fistula, bowel obstruction, inflammatory bowel disease, extensive bowel surgery, Crohn's disease, ulcerative colitis, or chronic diarrhoea.
  • People with evidence of unexplained air in the abdominal cavity that cannot be accounted for by a recent medical procedure or surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dongling Zou, M.D., Chongqing University Cancer Hospital

Phone: 13657690699

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chongqing University Cancer Hospital
Registry
ClinicalTrials.gov
Start date
13 April 2022
Est. completion
1 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Grade 3-4 neutropenia; Time to reconstruct haematopoietic function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov